Discovery of GS-8374, a potent human immunodeficiency virus type 1 protease inhibitor with a superior resistance profile

MedChemComm

Volumn 2, Issue 11, 2011, Pages 1093-1098

  He, Gong Xing ^a   Yang, Zheng Yu ^a   Williams, Matthew ^a   Callebaut, Christian ^a   Cihlar, Tomas ^a   Murray, Bernard P ^a   Yang, Chris ^a   Mitchell, Michael L ^a   Liu, Hongtao ^a   Wang, Jianying ^a   Arimilli, Murty ^a   Eisenberg, Eugene ^a   Stray, Kirsten M ^a   Tsai, Luong K ^a   Hatada, Marcos ^a   Chen, Xiaowu ^a   Chen, James M ^a   Wang, Yujin ^a   Lee, Melody S ^a   Strickley, Robert G ^a   Iwata, Quynh ^a   Zheng, Xubin ^a   Kim, Choung U ^a   Swaminathan, Swami ^a   Desai, Manoj C ^a   Lee, William A ^a   Xu, Lianhong ^a   more..

^a GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ATAZANAVIR; CYTOCHROME P450 3A; DARUNAVIR; GAG PROTEIN; GS 8374; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INDINAVIR; LOPINAVIR; NELFINAVIR; PLASMA PROTEIN; RITONAVIR; SAQUINAVIR; TIPRANAVIR; TMC 126; UNCLASSIFIED DRUG;

AEROBIC METABOLISM; ANIMAL EXPERIMENT; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG OXIDATION; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; ENTHALPY; ENTROPY; ENZYME INHIBITION; ENZYME STRUCTURE; FREE BINDING ENERGY; HUMAN; LIVER MICROSOME METABOLISM; NONHUMAN; PRIORITY JOURNAL; SOLVATION; STRUCTURE ACTIVITY RELATION; THERMODYNAMICS; VIRUS MUTATION; VIRUS RECOMBINANT;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 80455163191     PISSN: 20402503     EISSN: 20402511     Source Type: Journal    
DOI: 10.1039/c1md00147g     Document Type: Article

References (23)

1. F. J. Palela, Jr.K. M. Delaney A. C. Morrman M. O. Loveless J. Fuhrer G. A. Satten et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators N. Engl. J. Med. 1998 338 853 60 (Pubitemid 28135961)
2. C. Flexner HIV protease inhibitors N. Engl. J. Med. 1998 338 1281 1292
3. A. M. J. Wensing N. M. van Maarseveen M. Nijhuis Fifteen years of HIV protease inhibitors: raising the barrier to resistance Antiviral Res. 2010 85 59 74
4. G. Moyle Principle and practice of HIV-protease inhibitor pharmacoenhancement AIDS Med. 2001 2 105 113 (Pubitemid 33114749)
5. J. G. Gerber Using pharmacokinetics to optimize antiretroviral drug-drug interactions in the treatment of human immunodeficiency virus infection Clin. Infect. Dis. 2000 30 Suppl 2 S123 9
6. C. L. Cooper R. P. G. van Heeswijk K. Gallicano D. W. Cameron A review of low-dose ritonavir in protease inhibitor combination therapy Clin. Infect. Dis. 2003 36 1585 1592 (Pubitemid 36783344)
7. M. Barry F. Mulcahy C. Merry S. Gibbons D. Back Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection Clin. Pharmacokinet. 1999 36 289 304 (Pubitemid 29201737)
8. M. Youle Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients J. Antimicrob. Chemother. 2007 60 1195 1205 (Pubitemid 350176278)
9. K. H. Busse S. R. Penzak Pharmacological enhancement of protease inhibitor with ritonavir: an update Expert Rev. Clin. Pharmacol. 2008 1 533 545
10. L. Xu M. C. Desai Pharmacokinetic enhancers for HIV drugs Curr. Opinion in Investig. Drugs 2009 10 775 786
11. S. M. Hammer J. J. Eron P. Reiss R. T. Schooley M. A. Thompson S. Walmsley P. Cahn M. A. Fischl J. M. Gatell M. S. Hirsh D. M. Jacobsen J. S. G. Montaner D. D. Richman P. G. Yeni P. A. Volberding Antiretroviral treatment of adult HIV infection: 2008 recommendations of the international AIDS society USA panel J. Am. Med. Assoc. 2008 300 555 70
12. Panel on Antiretroviral Guidelines for Adults and Adolescent, Department of Health and Human Services (DHHS). Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. (January 10, 2011) 1-174 and references therein. Available at http://aidsinfo.nih.gov/contentfiles/ AdultandAdolescentGL.pdf
13. D. L. N. G. Surleraux A. Tahri W. G. Verschueren G. M. E. Pille H. A. de Kock T. H. M. Jonckers A. Peeters S. De Meyer A. Azijin R. Pauwels M.-P. de Bethune N. M. King M. Prabu-Jeyabalan C. A. Schiffer P. B. T. P. Wigerinck Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor J. Med. Chem. 2005 48 1813 1822 (Pubitemid 40396314)
14. A. Molla S. Vasavanonda G. Kumar H. L. Sham M. Johnson B. Grabowski J. F. Denissen W. Kohlbrenner J. J. Plattner J. M. Leonard D. W. Norbeck D. J. Kempf Human serum attenuates the activity of protease inhibitors toward wild-type and mutant huma immunodeficiency virus Virology 1998 250 255
15. A. K. Ghosh Y. Chen Synthesis and optical resolution of high affinity P2-ligand for HIV-1 protease inhibitors Tetrahedron Lett. 1995 36 505 508
16. C. Callebaut K. Stray L. Tsai M. Williams Z.-Y. Yang C. Cannizzaro S. Leavitt X. Liu K. Wang B. Murray A. Mulato M. Hatada T. Priskich N. Parkin S. Swaminathan W. A. Lee G.-X. He L. Xu T. Cihlar In vitro characterization of GS-8374, a novel phosphonate-containing inhibitor of HIV-1 protease with a favorable resistance profile AAC 2011 55 1366 1376
17. T. Cihlar G.-X. He X. Liu J. M. Chen M. Hatada S. Swaminathan M. J. McDermott Z.-Y. Yang A. S. Mulato X. Chen S. A. Leavitt K. M. Stray W. A. Lee Suppression of HIV-1 protease inhibitor resistance by phosphonate-mediated solvent anchoring J. Mol. Biol. 2006 363 635 647 (Pubitemid 44486216)
18. C. Callebaut; K. M. Stray; L. K. Tsai; L. Xu; W. A. Lee; T. Cihlar. In vitro HIV resistance selection to GS-8374, a novel phosphonate protease inhibitor: comparison with atazanavir, lopinavir and darunavir. 16th International HIV Drug Resistance Workshop 2007
19. A. Carrillo K. D. Stewart H. L. Sham D. W. Norbeck W. E. Kohlbrenner J. M. Leonard D. J. Kempt A. Molla In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor J Virology 1998 72 7532 7541 (Pubitemid 28377885)
20. Y.-F. Gong B. S. Robinson R. E. Rose C. Deminie T. P. Spicer D. Stock R. J. Colonno P.-F. Lin In vitro resistance profile of the human immunodeficiency viruse type 1 protease inhibitor BMS-232632 AAC 2000 44 2319 2326 (Pubitemid 30650874)
21. S. De Meyer H. Azijn D. Surleraux D. Jochmans A. Tahri R. Pauwels P. Wigerinck M.-P. de Béthune TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses including a broad range of clinical isolates AAC 2005 49 2314 2321 (Pubitemid 40734460)
22. L. Xu H. Liu B. P. Murray C. Callebaut M. S. Lee A. Hong R. G. Strickley L. K. Tsai K. M. Stray Y. Wang G. R. Rhodes M. C. Desai Cobicistat (GS-9350): a potent and selective inhibitor of human CYP3A as a novel pharmacoenhancer ACS Med. Chem. Lett. 2010 1 209 213
23. A. Mathias P. German B. P. Murray L. Wei A. Jain S. West D. Warren J. Hui B. P. Kearney Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity Clin. Pharmacol. Ther. 2010 86 322 329